Apeptico reports Phase II data for pulmonary product

Apeptico Forschung und Entwicklung GmbH (Vienna, Austria) said orally inhaled AP301 led to earlier onset and "more pronounced activation" of pulmonary edema clearance vs. placebo in a Phase IIa trial ...